Priyenka Thapa, MD
Infectious Disease · Little Rock, ARNPI 1023471885
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $658 of the $837 with a category attached, or 78.6%. 9 manufacturers reported payments, led by AbbVie at 29.5% of the total. Reporting peaked in 2023 at $454 and has fallen 57.4% since, to $194 in 2025.
Across 31 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$247
- Astellas Pharma US Inc$163
- Merck$99
- Novo Nordisk$94
- Paratek Pharmaceuticals, Inc.$83
- Melinta Therapeutics, LLC$44
- plus $107 from 3 others
What the payments were for
- Food & beverage$65879%
- Education$17921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $247 |
| Astellas Pharma US Inc | 3 | $163 |
| Merck | 5 | $99 |
| Novo Nordisk | 1 | $94 |
| Paratek Pharmaceuticals, Inc. | 4 | $83 |
| Melinta Therapeutics, LLC | 2 | $44 |
| Shionogi Inc | 2 | $44 |
| La Jolla Pharmaceutical Company | 2 | $42 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
How this compares
$837 in reported general payments places this provider in the 65th percentile of 36 infectious disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 14 | $9,253 |
| CeftriaxoneCeftriaxone Sodium | 25 | $1,186 |
| Cefazolin Sodium | 16 | $614 |
| Cephalexin | 13 | $75 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Little Rock
- Jeremy BariolaLittle Rock$2K
- Naveen PatilLittle Rock$1K
- Katherine FerrenLittle Rock$1K
- Mary BurgessLittle Rock$1K
- Dwight LindleyLittle Rock$671
- Ryan DareLittle Rock$411
- Brandon WalserLittle Rock$219
- Jessica FrazierLittle Rock$164
- Matthew BurnsLittle Rock$135
- Rebekah ThompsonLittle Rock$123
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.